Our pipeline for autoimmune diabetes is potentially game changing. Focusing on safe and specific interventions that have the promise to realize the true value of preemptive medicine. Spearheaded by Diamyd^®, an antigen-specific immunotherapy for individuals carrying a common risk gene (haplotype DR3-DQ2”), provides us with the opportunity to address up to 40 % of the millions of individuals at risk or diagnosed with autoimmune diabetes in the world.